Resumen
Mutations in Bcl-2–associated athanogene 3 (BAG3) were associated with skeletal muscle dysfunction and dilated cardiomyopathy. Retro-orbital injection of an adeno-associated virus serotype 9 expressing BAG3 (rAAV9-BAG3) significantly (p < 0.0001) improved left ventricular ejection fraction, fractional shortening, and stroke volume 9 days post-injection in mice with cardiac dysfunction secondary to a myocardial infarction. Furthermore, myocytes isolated from mice 3 weeks after injection showed improved cell shortening, enhanced systolic [Ca2+]i and increased [Ca2+]i transient amplitudes, and increased maximal L-type Ca2+ current amplitude. These results suggest that BAG3 gene therapy may provide a novel therapeutic option for the treatment of heart failure.
Idioma original | English (US) |
---|---|
Páginas (desde-hasta) | 647-656 |
Número de páginas | 10 |
Publicación | JACC: Basic to Translational Science |
Volumen | 1 |
N.º | 7 |
DOI | |
Estado | Published - 2016 |
Publicado de forma externa | Sí |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine